PSYCHOVEGETATIVE, ASTHENIC AND COGNITIVE IMPAIRMENT IN CONNECTIVE TISSUE DYSPLASIA: CHOICE OF OPTIMAL THERAPY


Cite item

Full Text

Abstract

The article presents the results of the evaluation of the efficacy and safety of use of acetyl-L-carnitine (Carnicetine) in asthenic, psychovegetative and cognitive impairment in 60 patients with connective tissue dysplasia in comparison with non-pharmacological and bracing therapy. It was found that the therapy with Carnicetine reduces the manifestations of asthenia, reduces neurological and vegetative symptoms with significant improvement in all cognitive scales.

References

  1. Кадурина Т.И., Горбунова В.Н. Дисплазия соединительной ткани. Руководство для врачей. СПб., 2009. 714 с.
  2. Копелевич В.М. Применение ацетил L-карнитина (карницитин) в клинической практике. Методическое пособие. М., 2010, 28 с.
  3. Копелевич В.М. Витаминоподобные соединения L-карнитина и ацетил-Lкарнитина:от биохимических исследований к медицинскому применению // Укр. биохим. журн. 2005. № 77. С. 24-45.
  4. Нечаева Г.И., Викторова И.А. Дисплазии соединительной ткани: терминология, диагностика, тактика ведения пациентов. Омск, 2007. 188 с.
  5. Сухоруков В.С. К разработке рациональных основ энерготропной терапии // Рациональная фармакотерапия 2007. № 2. С. 40-47.
  6. Торшин И.Ю., Громова О.А. Дисплазии соединительной ткани, магний и нуклеотидные полиморфизмы // Кардиология 2008. № 10. С. 57-64.
  7. Шабалов Н.П., Арсентьев В.Г. Педиатрия: национальное руководство. М., 2009. № 1. С. 298-320.
  8. Aliev G, Liu J, ShenkJC, et al. Neuronal mitochondrial energy metabolism. Neuropharmacol 2008;55(2):223-9.
  9. Angelucci L, Ramacci MT, Taglialatela G, et al. Nerve growth factor binding in agedrat centralnervous system:effect of acetyl-L-carnitine. J Neurosci Res 1988;20:491-96.
  10. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983;63:1420-80.
  11. Castorina M, Ambrosini AM, Pacific L, et al. Agt-dependent loss of NMDA receptors in hippocampus, stpiatum andfrontal cortex of the rat: prevention by acetyl-Lcarnitine. Neurochem Res 1994;19:795-98.
  12. Harsing LG Jr, Sershen H, Toth E, et al. Acetyl-Lcarnitine releases dopamine in ratcorpus striatum: an in vivo microdialysis study. Eur J pharmacol 1992;218:117-21.
  13. Imperato A, Rammacci MT, Angelucci L. Acetyl-Lcarnitine enhances acetylcholine release in the striatum and hippocampus of awakefreely moving rats. Neurosci Lett 1989;107:251-55.
  14. Liu J, Head E, Kuratsune H, et al. Comparison of the effekts of L-carnitine Ann NY Acad Sci 2004;1033:117-31.
  15. Pettegrew JW, Levine J, McClure RJ, Acetyl-Lcarnitine physical-chemical, metabolic,andtherapeutic properties: relevance for its mode of action in Alzheimers disease and geriatric depression. Molecul Psychiat 2000;5:616-32.
  16. Tempesta E, Janiri L, Pirrongelli C. Stereospecific effects of acetylcarnitineon the spontaneous activity of brainstem neurones and their responses to acetyicholine and serotonin. Neuropharmacology 1985;24:43-50.
  17. Tsuji A. Functional relevance of carnitine transporter OCTN2 tobrain distribution of L-carnitine and acetyl-Lcarnitine across the blood-brainbarrier. J Neirochem 2001;79:959-69.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies